您的购物车当前为空
别名 KX1004, KX1 004
KX1-004 是非 ATP 竞争性 Src-PTK 抑制剂,IC50=40 μM。它能够保护耳蜗,使其免受有害噪音的影响,并防止噪音引起的听力损失 (NIHL)。


为众多的药物研发团队赋能,
让新药发现更简单!
KX1-004 是非 ATP 竞争性 Src-PTK 抑制剂,IC50=40 μM。它能够保护耳蜗,使其免受有害噪音的影响,并防止噪音引起的听力损失 (NIHL)。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 378 | In stock | |
| 5 mg | ¥ 892 | In stock | |
| 10 mg | ¥ 1,450 | In stock | |
| 25 mg | ¥ 2,750 | In stock | |
| 50 mg | ¥ 3,930 | In stock | |
| 100 mg | ¥ 5,730 | In stock | |
| 200 mg | ¥ 7,830 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 983 | In stock |
KX1-004 相关产品
| 产品描述 | KX1-004, a potential protective drug for NIHL, is an effective small molecule inhibitor of Src-PTK. |
| 靶点活性 | Src PTK:40 μM |
| 激酶实验 | The Lck HTRF kinase assay involves ATP-dependent phosphorylation of a biotinylated substrate peptide of gastrin in the presence or absence of inhibitor compound. The final concentration of gastrin is 1.2 μM. The final concentration of ATP is 0.5 μM (Km app =0.6±0.1 μM), and the final concentration of Lck (a GST-kinase domain fusion (AA 225?509)) is 250 pM. Buffer conditions are as follows: 50 mM HEPES pH=7.5, 50 mM NaCl, 20 mM MgCl2, 5 mM MnCl2, 2 mM DTT, 0.05% BSA. The assay is quenched and stopped with 160 μL of detection reagent. Detection reagents are as follows: Buffer made of 50 mM Tris, pH=7.5, 100 mM NaCl, 3 mM EDTA, 0.05% BSA, 0.1% Tween20. Prior to reading, Streptavidin allophycocyanin (SA-APC) is added at a final concentration in the assay of 0.0004 mg/mL, along with europilated anti-phosphotyrosine Ab (Eu-anti-PY) at a final conc of 0.025 nM. The assay plate is read in a Discovery fluorescence plate reader with excitation at 320 nm and emission at 615 and 655 nm[1]. |
| 别名 | KX1004, KX1 004 |
| 分子量 | 284.29 |
| 分子式 | C16H13FN2O2 |
| CAS No. | 518058-84-9 |
| Smiles | OC1=CC=CC(CNC(=O)C2=CC3=CC(F)=CC=C3N2)=C1 |
| 密度 | 1.382 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 60 mg/mL (211.05 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.04 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容